The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Effect of Statin Therapy on C-Reactive Protein Levels: The Pravastatin Inflammation/CRP Evaluation (PRINCE): A Randomized Trial and Cohort Study
Open accessAbstract
CONTEXT: Plasma levels of the inflammatory biomarker C-reactive protein (CRP) predict cardiovascular risk, and retrospective studies suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) may lower CRP in a manner largely independent of low-density lipoprotein cholesterol (LDL-C). However, prospective trial data directly evaluating this anti-inflammatory effect of statins are not available. OBJECTIVE: To test the hypothesis that pravastatin has anti-inflammatory effects as evidenced by CRP reduction. DESIGN, SETTING, AND PARTICIPANTS: Community-based, prospective, randomized, double-blind trial including 1702 men and women with no prior history of cardiovascular disease (primary prevention cohort) and open-label study including 1182 patients with known cardiovascular disease (secondary prevention cohort) who provided at least baseline and 12-week blood samples. The study was conducted in US office-based practices from February to December 2000. INTERVENTIONS: Participants in the double-blind primary prevention trial were randomly assigned to receive 40 mg/d of pravastatin (n = 865) or placebo (n = 837) for 24 weeks. Participants in the secondary prevention cohort received 40 mg/d of open-label pravastatin for 24 weeks. MAIN OUTCOME MEASURE: Change in CRP levels from baseline to 24 weeks. RESULTS: In the primary prevention trial, compared with placebo, pravastatin reduced median CRP levels by 16.9% (P<.001) at 24 weeks, reflecting a decrease of 0.02 mg/dL in the pravastatin group while no change in CRP levels was observed in the placebo group. This effect was seen as early as 12 weeks (median reduction in CRP with pravastatin, 14.7%; P<.001) and was present among all prespecified subgroups according to sex, age, smoking status, body mass index, baseline lipid levels, presence of diabetes, and use of aspirin or hormone replacement therapy. No significant association was observed between baseline CRP and baseline LDL-C levels, end-of-study CRP and end-of-study LDL-C levels, or change in CRP and change in LDL-C levels over time. In linear regression analyses, the only significant predictors of change in CRP on a log scale were randomized pravastatin allocation and baseline CRP levels (P<.001 for both). Similar reductions in CRP levels were observed at 12 weeks (-14.3%) and 24 weeks (-13.1%) in the secondary prevention cohort treated with pravastatin (P<.005 for both). CONCLUSIONS: In this prospective trial, pravastatin reduced CRP levels at both 12 and 24 weeks in a largely LDL-C-independent manner. These data provide evidence that statins may have anti-inflammatory effects in addition to lipid-lowering effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
Hulley, S. (1998) · JAMA · doi:10.1001/jama.280.7.605 · Cited by 6,216
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citationInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Ridker, P. M., Rifai, N., Pfeffer, M. A., Sacks, F., & Braunwald, E. (1999) · Circulation · doi:10.1161/01.cir.100.3.230 · Cited by 1,478
Self-citationRidker, P. M. (2001) · Circulation · doi:10.1161/01.cir.103.13.1813 · Cited by 1,402
Self-citation
Cited by
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Self-citationRosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Self-citationPearson, T. A., Mensah, G. A., Alexander, R. W., Anderson, J. L., Cannon, R. O., Criqui, M., Fadl, Y. Y., Fortmann, S. P., Hong, Y., Myers, G. L., et al. (2003) · Circulation · doi:10.1161/01.cir.0000052939.59093.45 · Cited by 6,401
Self-citationEndothelial Cell Dysfunction and the Pathobiology of Atherosclerosis
Gimbrone, M. A., & García-Cardeña, G. (2016) · Circulation Research · doi:10.1161/circresaha.115.306301 · Cited by 3,476
Role of Oxidative Modifications in Atherosclerosis
Stocker, R., & Keaney, J. F. (2004) · Physiological Reviews · doi:10.1152/physrev.00047.2003 · Cited by 2,624
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Self-citationC-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Self-citationEstrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
Thompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
A copy number variation morbidity map of developmental delay
Cooper, G. M., Coe, B. P., Girirajan, S., Rosenfeld, J. A., Vu, T. H., Baker, C., Williams, C., Stalker, H., Hamid, R., Hannig, V., et al. (2011) · Nature Genetics · doi:10.1038/ng.909 · Cited by 1,351
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392
Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease
Nissen, S. E., Tuzcu, E. M., Schoenhagen, P., Crowe, T., Sasiela, W. J., Tsai, J., Orazem, J., Magorien, R. D., O'Shaughnessy, C., & Ganz, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042000 · Cited by 1,325
Inflammation as a Cardiovascular Risk Factor
Willerson, J. T., & Ridker, P. M. (2004) · Circulation · doi:10.1161/01.cir.0000129535.04194.38 · Cited by 1,304
Self-citationEffect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk
Meier-Ewert, H. K., Ridker, P. M., Rifai, N., Regan, M. M., Price, N. J., Dinges, D. F., & Mullington, J. M. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.07.050 · Cited by 1,195
Self-citationObstructive Sleep Apnea: Implications for Cardiac and Vascular Disease
Shamsuzzaman, A. S. M., Gersh, B. J., & Somers, V. K. (2003) · JAMA · doi:10.1001/jama.290.14.1906 · Cited by 1,188
Inflammation and cardiovascular disease mechanisms
Libby, P. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.2.456s · Cited by 1,104
Jellinger, P. S., Handelsman, Y., Rosenblit, P. D., Bloomgarden, Z. T., Fonseca, V. A., Garber, A. J., Grunberger, G., Guerin, C. K., Bell, D. S. H., Mechanick, J. I., et al. (2017) · Endocrine Practice · doi:10.4158/ep171764.appgl · Cited by 1,094
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Self-citationElevated C-Reactive Protein in Patients With Obstructive Sleep Apnea
Shamsuzzaman, A. S. M., Winnicki, M., Lanfranchi, P., Wolk, R., Kara, T., Accurso, V., & Somers, V. K. (2002) · Circulation · doi:10.1161/01.cir.0000018948.95175.03 · Cited by 974
Beneficial Cardiovascular Pleiotropic Effects of Statins
Davignon, J. (2004) · Circulation · doi:10.1161/01.cir.0000131517.20177.5a · Cited by 955
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942
Self-citationAnti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms
Jain, M. K., & Ridker, P. M. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1901 · Cited by 915
Self-citationHaffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884
Evacetrapib and cardiovascular outcomes in high-risk vascular disease
Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801
Clinical biomarkers in drug discovery and development
Frank, R., & Hargreaves, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2
Jacobson, T. A., Maki, K. C., Orringer, C. E., Jones, P. H., Kris-Etherton, P., Sikand, G., La Forge, R., Daniels, S. R., Wilson, D. P., Morris, P. B., et al. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.09.002 · Cited by 784
“Conversely, there are a number of studies demonstrating that hs-CRP declines with the use of statins in the general population.(615) In JUPITER, the 44% risk reduction with the use of rosuvastatin was associated with a decline in hs-CRP.”
BackgroundMeta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770
Novel Clinical Markers of Vascular Wall Inflammation
Blake, G. J., & Ridker, P. M. (2001) · Circulation Research · doi:10.1161/hh2101.099270 · Cited by 754
Self-citationA Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism
Glynn, R. J., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900241 · Cited by 752
Self-citationDavidovici, B. B., Sattar, N., Jörg, P. C., Puig, L., Emery, P., Barker, J. N., van de Kerkhof, P., Ståhle, M., Nestle, F. O., Girolomoni, G., et al. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.103 · Cited by 711
Inflammatory bio‐markers and cardiovascular risk prediction
Blake, G. J., & Ridker, P. M. (2002) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2002.01019.x · Cited by 702
Self-citationOxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease
Cachofeiro, V., Goicochea, M., de Vinuesa, S. G., Oubiña, P., Lahera, V., & Luño, J. (2008) · Kidney International · doi:10.1038/ki.2008.516 · Cited by 662
C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk
Ridker, P. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.052 · Cited by 623
Self-citationTargeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
Mevalonate pathway: A review of clinical and therapeutical implications
Buhaescu, I., & Izzedine, H. (2007) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2007.03.016 · Cited by 620
Population analysis of large copy number variants and hotspots of human genetic disease
Itsara, A., Cooper, G. M., Baker, C., Girirajan, S., Li, J., Absher, D., Krauss, R. M., Myers, R. M., Ridker, P. M., Chasman, D. I., et al. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2008.12.014 · Cited by 591
Self-citationDepression and immune function
Kiecolt-Glaser, J. K., & Glaser, R. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00309-4 · Cited by 571
“A prospective trial of statins produced reductions in CRP, providing evidence that these drugs have anti-inflammatory effects in addition to their ability to lower lipids [45].”
BackgroundInflammation and Cardiovascular Disease: From Pathogenesis to Therapeutic Target
Golia, E., Limongelli, G., Natale, F., Fimiani, F., Maddaloni, V., Pariggiano, I., Bianchi, R., Crisci, M., D’Acierno, L., Giordano, R., et al. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0435-z · Cited by 560
Shim, H., Chasman, D. I., Smith, J. D., Mora, S., Ridker, P. M., Nickerson, D. A., Krauss, R. M., & Stephens, M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120758 · Cited by 558
Self-citationKell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Is atrial fibrillation an inflammatory disorder?
Boos, C. J., Anderson, R. A., & Lip, G. Y. H. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi645 · Cited by 552
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Self-citationC-Reactive Protein Upregulates Angiotensin Type 1 Receptors in Vascular Smooth Muscle
Wang, C.-H., Li, S.-H., Weisel, R. D., Fedak, P. W. M., Dumont, A. S., Szmitko, P., Li, R.-K., Mickle, D. A. G., & Verma, S. (2003) · Circulation · doi:10.1161/01.cir.0000061916.95736.e5 · Cited by 545
Wood, A. M., White, I. R., & Thompson, S. G. (2004) · Clinical Trials · doi:10.1191/1740774504cn032oa · Cited by 543
Jellinger, P. S., Smith, D. A., Mehta, A. E., Ganda, O., Handelsman, Y., Rodbard, H. W., Shepherd, M. D., & Seibel, J. A. (2012) · Endocrine Practice · doi:10.4158/ep.18.s1.1 · Cited by 533
Poldermans, D., Bax, J. J., Kertai, M. D., Krenning, B., Westerhout, C. M., Schinkel, A. F. L., Thomson, I. R., Lansberg, P. J., Fleisher, L. A., Klein, J., et al. (2003) · Circulation · doi:10.1161/01.cir.0000066286.15621.98 · Cited by 484
Patti, G., Pasceri, V., Colonna, G., Miglionico, M., Fischetti, D., Sardella, G., Montinaro, A., & Di Sciascio, G. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.025 · Cited by 483
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Bermudez, E. A., Rifai, N., Buring, J., Manson, J. E., & Ridker, P. M. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000029781.31325.66 · Cited by 469
Self-citationPasceri, V., Patti, G., Nusca, A., Pristipino, C., Richichi, G., & Di Sciascio, G. (2004) · Circulation · doi:10.1161/01.cir.0000137828.06205.87 · Cited by 466
High-sensitivity C-reactive proteinClinical importance
BASSUK, S., RIFAI, N., & RIDKER, P. (2004) · Current Problems in Cardiology · doi:10.1016/s0146-2806(04)00074-x · Cited by 464
Self-citationPharmacogenetic Study of Statin Therapy and Cholesterol Reduction
Chasman, D. I. (2004) · JAMA · doi:10.1001/jama.291.23.2821 · Cited by 453
Nicklas, B. J., Ambrosius, W., Messier, S. P., Miller, G. D., Penninx, B. W., Loeser, R. F., Palla, S., Bleecker, E., & Pahor, M. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/79.4.544 · Cited by 443
S. Antonopoulos, A., Margaritis, M., Lee, R., Channon, K., & Antoniades, C. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504803 · Cited by 432
Kopp, H. P., Kopp, C. W., Festa, A., Krzyzanowska, K., Kriwanek, S., Minar, E., Roka, R., & Schernthaner, G. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000073313.16135.21 · Cited by 427
Review Articles: Inflammation in End‐stage Renal Disease: Sources, Consequences, and Therapy
Stenvinkel, P., & Alvestrand, A. (2002) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2002.00083.x · Cited by 425
Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events
Ridker, P. M., Brown, N. J., Vaughan, D. E., Harrison, D. G., & Mehta, J. L. (2004) · Circulation · doi:10.1161/01.cir.0000133444.17867.56 · Cited by 422
Self-citationRidker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000100688.17280.e6 · Cited by 421
Self-citationNode, K., Fujita, M., Kitakaze, M., Hori, M., & Liao, J. K. (2003) · Circulation · doi:10.1161/01.cir.0000084539.58092.de · Cited by 414
Kinlay, S., Schwartz, G. G., Olsson, A. G., Rifai, N., Leslie, S. J., Sasiela, W. J., Szarek, M., Libby, P., & Ganz, P. (2003) · Circulation · doi:10.1161/01.cir.0000091404.09558.af · Cited by 405
Self-citationFliser, D., Buchholz, K., & Haller, H. (2004) · Circulation · doi:10.1161/01.cir.0000140265.21608.8e · Cited by 404
Coming of Age of C-Reactive Protein: Using Inflammation Markers in Cardiology
Yeh, E. T. H., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000053731.05365.5a · Cited by 403
Association between dietary fiber and serum C-reactive protein
Ma, Y., Griffith, J. A., Chasan-Taber, L., Olendzki, B. C., Jackson, E., Stanek, E. J., Li, W., Pagoto, S. L., Hafner, A. R., & Ockene, I. S. (2006) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/83.4.760 · Cited by 396
Koushki, K., Shahbaz, S. K., Mashayekhi, K., Sadeghi, M., Zayeri, Z. D., Taba, M. Y., Banach, M., Al-Rasadi, K., Johnston, T. P., & Sahebkar, A. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08791-9 · Cited by 382
Associations Between Cardiorespiratory Fitness and C-Reactive Protein in Men
Church, T. S., Barlow, C. E., Earnest, C. P., Kampert, J. B., Priest, E. L., & Blair, S. N. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000036611.77940.f8 · Cited by 382
Helfand, M., Buckley, D. I., Freeman, M., Fu, R., Rogers, K., Fleming, C., & Humphrey, L. L. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-7-200910060-00010 · Cited by 382
C-reactive protein and other inflammatory risk markers in acute coronary syndromes
Blake, G. J., & Ridker, P. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)02953-4 · Cited by 367
Self-citationC‐reactive protein and coronary heart disease: a critical review
Casas, J. P., Shah, T., Hingorani, A. D., Danesh, J., & Pepys, M. B. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2008.02015.x · Cited by 366
Inflammatory biomarkers in coronary artery disease
Zakynthinos, E., & Pappa, N. (2009) · Journal of Cardiology · doi:10.1016/j.jjcc.2008.12.007 · Cited by 359
Seddon, J. M. (2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.6.774 · Cited by 354
SÖDERBERG‐NAUCLÉR, C. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01618.x · Cited by 349
Inflammation in Atherosclerosis and Implications for Therapy
Paoletti, R., Gotto, A. M., & Hajjar, D. P. (2004) · Circulation · doi:10.1161/01.cir.0000131514.71167.2e · Cited by 349
Cardiac cachexia: A systematic overview
von Haehling, S., Lainscak, M., Springer, J., & Anker, S. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.009 · Cited by 348
Tsimikas, S., Willerson, J. T., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.066 · Cited by 335
Self-citationMarx, N., Kehrle, B., Kohlhammer, K., Grüb, M., Koenig, W., Hombach, V., Libby, P., & Plutzky, J. (2002) · Circulation Research · doi:10.1161/01.res.0000014225.20727.8f · Cited by 331
Relative Burden of Large CNVs on a Range of Neurodevelopmental Phenotypes
Girirajan, S., Brkanac, Z., Coe, B. P., Baker, C., Vives, L., Vu, T. H., Shafer, N., Bernier, R., Ferrero, G. B., Silengo, M., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002334 · Cited by 324
Kasiske, B., Cosio, F. G., Beto, J., Bolton, K., Chavers, B. M., Grimm, R., Levin, A., Masri, B., Parekh, R., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 316
Elevated Serum C-Reactive Protein Levels and Early Arterial Changes in Healthy Children
Järvisalo, M. J., Harmoinen, A., Hakanen, M., Paakkunainen, U., Viikari, J., Hartiala, J., Lehtimäki, T., Simell, O., & Raitakari, O. T. (2002) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000024222.06463.21 · Cited by 315
Pleiotropic Effects of Statins: Lipid Reduction and Beyond
McFarlane, S. I. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.4.1451 · Cited by 314
A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma.
McKay, A., Leung, B. P., McInnes, I. B., Thomson, N. C., & Liew, F. Y. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2903 · Cited by 309
Ridker, P. M., & Torres, J. (2006) · JAMA · doi:10.1001/jama.295.19.2270 · Cited by 303
Self-citationReduction in C-reactive protein through cardiac rehabilitation and exercise training
Milani, R. V., Lavie, C. J., & Mehra, M. R. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.041 · Cited by 302
C-reactive protein levels and clinically important predictive outcomes in stable COPD patients
de Torres, J. P., Cordoba-Lanus, E., López-Aguilar, C., Muros de Fuentes, M., Montejo de Garcini, A., Aguirre-Jaime, A., Celli, B. R., & Casanova, C. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00109605 · Cited by 297
Risk factors for venous thromboembolism
Heit, J. A. (2003) · Clinics in Chest Medicine · doi:10.1016/s0272-5231(02)00077-1 · Cited by 294
COVID-19 and comorbidities: a systematic review and meta-analysis
Gold, M. S., Sehayek, D., Gabrielli, S., Zhang, X., McCusker, C., & Ben-Shoshan, M. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1786964 · Cited by 289
Blum, A., & Shamburek, R. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.022 · Cited by 287
Aktas, O., Waiczies, S., Smorodchenko, A., Dörr, J., Seeger, B., Prozorovski, T., Sallach, S., Endres, M., Brocke, S., Nitsch, R., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021425 · Cited by 282
Endothelial inflammation in insulin resistance
SJOHOLM, A., & NYSTROM, T. (2005) · The Lancet · doi:10.1016/s0140-6736(05)70804-7 · Cited by 278
Katsimaglis, G., Danias, P. G., Danias, P. G., O'Neil-Callahan, K., Ryan, J., Mosby, C., Danias, P. G., Katsimaglis, G., Ioannidis, J. P. A., Ioannidis, J. P. A., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.048 · Cited by 276
Inflammation and Infection in Clinical Stroke
Emsley, H. C. A., & Tyrrell, P. J. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200212000-00001 · Cited by 276
C‐Reactive Protein (CRP)‐Lowering Agents
Prasad, K. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00033.x · Cited by 272
RIDKER, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 270
Self-citationAlbert, M. A., Glynn, R. J., & Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000080289.72166.cf · Cited by 269
Self-citationChen, M.-L., Yi, L., Jin, X., Liang, X.-Y., Zhou, Y., Zhang, T., Xie, Q., Zhou, X., Chang, H., Fu, Y.-J., et al. (2013) · Autophagy · doi:10.4161/auto.26336 · Cited by 268
Beyond lipid lowering: the role of statins in vascular protection
Liao, J. K. (2002) · International Journal of Cardiology · doi:10.1016/s0167-5273(02)00195-x · Cited by 266
Immune Mechanisms in Heart Failure
Zhang, Y., Bauersachs, J., & Langer, H. F. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.942 · Cited by 262
Ridker, P. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00774-4 · Cited by 260
Self-citationPsychosocial Factors and Inflammation in the Multi-Ethnic Study of Atherosclerosis
Ranjit, N. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.2.174 · Cited by 260
Nicklas, B. J. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040769 · Cited by 259
Metadata
- Authors
- Albert, M. A., Danielson, E., Rifai, N., Ridker, P. M., & for the PRINCE Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-07-04
- Volume
- 286
- Issue
- 1
- Pages
- 64
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2070396041
- Cited by
- 1,641
- References
- 30
- FWCI
- 112.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.